Cargando…
Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer
In estrogen receptor (ER)-positive breast cancer, changes in biomarker expression after neoadjuvant therapy indicate the therapeutic response and are prognostic. However, there is limited information about the biomarker alteration caused by neoadjuvant endocrine therapy in ER-positive and human epid...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866043/ https://www.ncbi.nlm.nih.gov/pubmed/36676023 http://dx.doi.org/10.3390/life13010074 |
_version_ | 1784875990744301568 |
---|---|
author | Long, Mengping You, Chong Song, Qianqian Hu, Lina X. J. Guo, Zhaorong Yao, Qian Hou, Wei Sun, Wei Liang, Baosheng Zhou, Xiao-Hua Liu, Yiqiang Hu, Taobo |
author_facet | Long, Mengping You, Chong Song, Qianqian Hu, Lina X. J. Guo, Zhaorong Yao, Qian Hou, Wei Sun, Wei Liang, Baosheng Zhou, Xiao-Hua Liu, Yiqiang Hu, Taobo |
author_sort | Long, Mengping |
collection | PubMed |
description | In estrogen receptor (ER)-positive breast cancer, changes in biomarker expression after neoadjuvant therapy indicate the therapeutic response and are prognostic. However, there is limited information about the biomarker alteration caused by neoadjuvant endocrine therapy in ER-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. We recruited ER-positive/HER2-negative breast cancer patients who received neoadjuvant chemotherapy (NCT), neoadjuvant endocrine therapy (NET), or sequential neoadjuvant endocrine-chemotherapy (NECT) at Peking University Cancer Hospital from 2015 to 2021. A total of 579 patients had paired immunohistochemistry information in both diagnostic biopsy samples and post-neoadjuvant therapy surgical samples. Through a paired comparison of the immunohistochemical information in pre-treatment and post-treatment samples, we found that progesterone receptor (PR) expression reductions were more frequent than ER expression reductions (70.8% vs. 35.2%) after neoadjuvant therapy. The percentage of patients who had a decreased Ki-67 index in the post-operative samples was similar in the three groups (79.8% vs. 79.7% vs. 78.4%). Moreover, PR losses caused by NET were related to low baseline PR expression (p = 0.001), while we did not find a significant association between PR losses and Ki-67 reductions (p = 0.428) or ER losses (p = 0.274). All three types of neoadjuvant therapies caused a reduction in ER, PR, and Ki-67 expression. In conclusion, we found that PR loss after NET was only significantly related to low baseline PR expression, and there is no significant difference in the extent of prognostic factor change including Ki-67 and ER between the PR loss and non-loss groups. |
format | Online Article Text |
id | pubmed-9866043 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98660432023-01-22 Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer Long, Mengping You, Chong Song, Qianqian Hu, Lina X. J. Guo, Zhaorong Yao, Qian Hou, Wei Sun, Wei Liang, Baosheng Zhou, Xiao-Hua Liu, Yiqiang Hu, Taobo Life (Basel) Article In estrogen receptor (ER)-positive breast cancer, changes in biomarker expression after neoadjuvant therapy indicate the therapeutic response and are prognostic. However, there is limited information about the biomarker alteration caused by neoadjuvant endocrine therapy in ER-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. We recruited ER-positive/HER2-negative breast cancer patients who received neoadjuvant chemotherapy (NCT), neoadjuvant endocrine therapy (NET), or sequential neoadjuvant endocrine-chemotherapy (NECT) at Peking University Cancer Hospital from 2015 to 2021. A total of 579 patients had paired immunohistochemistry information in both diagnostic biopsy samples and post-neoadjuvant therapy surgical samples. Through a paired comparison of the immunohistochemical information in pre-treatment and post-treatment samples, we found that progesterone receptor (PR) expression reductions were more frequent than ER expression reductions (70.8% vs. 35.2%) after neoadjuvant therapy. The percentage of patients who had a decreased Ki-67 index in the post-operative samples was similar in the three groups (79.8% vs. 79.7% vs. 78.4%). Moreover, PR losses caused by NET were related to low baseline PR expression (p = 0.001), while we did not find a significant association between PR losses and Ki-67 reductions (p = 0.428) or ER losses (p = 0.274). All three types of neoadjuvant therapies caused a reduction in ER, PR, and Ki-67 expression. In conclusion, we found that PR loss after NET was only significantly related to low baseline PR expression, and there is no significant difference in the extent of prognostic factor change including Ki-67 and ER between the PR loss and non-loss groups. MDPI 2022-12-27 /pmc/articles/PMC9866043/ /pubmed/36676023 http://dx.doi.org/10.3390/life13010074 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Long, Mengping You, Chong Song, Qianqian Hu, Lina X. J. Guo, Zhaorong Yao, Qian Hou, Wei Sun, Wei Liang, Baosheng Zhou, Xiao-Hua Liu, Yiqiang Hu, Taobo Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer |
title | Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer |
title_full | Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer |
title_fullStr | Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer |
title_full_unstemmed | Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer |
title_short | Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer |
title_sort | biomarker alteration after neoadjuvant endocrine therapy or chemotherapy in estrogen receptor-positive breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866043/ https://www.ncbi.nlm.nih.gov/pubmed/36676023 http://dx.doi.org/10.3390/life13010074 |
work_keys_str_mv | AT longmengping biomarkeralterationafterneoadjuvantendocrinetherapyorchemotherapyinestrogenreceptorpositivebreastcancer AT youchong biomarkeralterationafterneoadjuvantendocrinetherapyorchemotherapyinestrogenreceptorpositivebreastcancer AT songqianqian biomarkeralterationafterneoadjuvantendocrinetherapyorchemotherapyinestrogenreceptorpositivebreastcancer AT hulinaxj biomarkeralterationafterneoadjuvantendocrinetherapyorchemotherapyinestrogenreceptorpositivebreastcancer AT guozhaorong biomarkeralterationafterneoadjuvantendocrinetherapyorchemotherapyinestrogenreceptorpositivebreastcancer AT yaoqian biomarkeralterationafterneoadjuvantendocrinetherapyorchemotherapyinestrogenreceptorpositivebreastcancer AT houwei biomarkeralterationafterneoadjuvantendocrinetherapyorchemotherapyinestrogenreceptorpositivebreastcancer AT sunwei biomarkeralterationafterneoadjuvantendocrinetherapyorchemotherapyinestrogenreceptorpositivebreastcancer AT liangbaosheng biomarkeralterationafterneoadjuvantendocrinetherapyorchemotherapyinestrogenreceptorpositivebreastcancer AT zhouxiaohua biomarkeralterationafterneoadjuvantendocrinetherapyorchemotherapyinestrogenreceptorpositivebreastcancer AT liuyiqiang biomarkeralterationafterneoadjuvantendocrinetherapyorchemotherapyinestrogenreceptorpositivebreastcancer AT hutaobo biomarkeralterationafterneoadjuvantendocrinetherapyorchemotherapyinestrogenreceptorpositivebreastcancer |